Molecular Targets in Cholangiocarcinoma

Colm J. O’Rourke, Patricia Munoz‐Garrido, Jesper B. Andersen – 18 April 2020 – Cholangiocarcinoma (CCA) encompasses a heterogeneous collection of malignancies for which diagnostic biomarkers are lacking and population screening is infeasible because of its status as a rare disease. Coupled with high postsurgical recurrence rates among the minority of patients diagnosed at resectable stages, systemic clinical management will inevitably be required for the majority of patients with CCA with recurrent and advanced disease.

Loss of c‐Jun N‐terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma

Francisco Javier Cubero, Mohamed Ramadan Mohamed, Marius M. Woitok, Gang Zhao, Maximilian Hatting, Yulia A. Nevzorova, Chaobo Chen, Johannes Haybaeck, Alain Bruin, Matias A. Avila, Mark V. Boekschoten, Roger J. Davis, Christian Trautwein – 16 April 2020 – Targeted inhibition of the c‐Jun N‐terminal kinases (JNKs) has shown therapeutic potential in intrahepatic cholangiocarcinoma (CCA)‐related tumorigenesis. However, the cell‐type‐specific role and mechanisms triggered by JNK in liver parenchymal cells during CCA remain largely unknown.

PPARγ Coactivator‐1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ–Dependent WNT/β‐Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis

Qiaozhu Zuo, Jia He, Shu Zhang, Hui Wang, Guangzhi Jin, Haojie Jin, Zhuoan Cheng, Xuemei Tao, Chengtao Yu, Botai Li, Chen Yang, Siying Wang, Yuanyuan Lv, Fangyu Zhao, Ming Yao, Wenming Cong, Cun Wang, Wenxin Qin – 16 April 2020

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement

Oren K. Fix, Bilal Hameed, Robert J. Fontana, Ryan M. Kwok, Brendan M. McGuire, David C. Mulligan, Daniel S. Pratt, Mark W. Russo, Michael L. Schilsky, Elizabeth C. Verna, Rohit Loomba, David E. Cohen, Jorge A. Bezerra, K. Rajender Reddy, Raymond T. Chung – 16 April 2020

Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation

Siamak Salehi, Oliver D. Tavabie, Suman Verma, Mark J. W. McPhail, Farzin Farzaneh, William Bernal, Krish Menon, Kosh Agarwal, Varuna R. Aluvihare – 16 April 2020 – We previously demonstrated a distinct hepatic microRNA (miRNA) signature (down‐regulation of miRNA‐23a, ‐150, ‐ 200b, ‐503, and ‐663 and up‐regulation of miRNA‐20a) is associated with successful regeneration in auxiliary liver transplantation (ALT). This study aimed to evaluate whether the serum expression of this regeneration‐linked miRNA signature is associated with clinical outcomes in acute and chronic liver disease.

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement

Oren K. Fix, Bilal Hameed, Robert J. Fontana, Ryan M. Kwok, Brendan M. McGuire, David C. Mulligan, Daniel S. Pratt, Mark W. Russo, Michael L. Schilsky, Elizabeth C. Verna, Rohit Loomba, David E. Cohen, Jorge A. Bezerra, K. Rajender Reddy, Raymond T. Chung – 16 April 2020

Subscribe to